Marinus Pharmaceuticals (NASDAQ:MRNS) was downgraded by investment analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.

A number of other research analysts have also weighed in on the stock. ValuEngine lowered shares of Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. JMP Securities reaffirmed an “outperform” rating and issued a $11.00 price objective (up from $5.00) on shares of Marinus Pharmaceuticals in a research note on Tuesday, September 12th.

Shares of Marinus Pharmaceuticals (NASDAQ MRNS) traded up $2.45 during trading hours on Thursday, reaching $8.64. 12,930,426 shares of the company traded hands, compared to its average volume of 1,220,302. Marinus Pharmaceuticals has a fifty-two week low of $0.82 and a fifty-two week high of $8.90.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.02.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jennison Associates LLC raised its position in Marinus Pharmaceuticals by 108.1% in the second quarter. Jennison Associates LLC now owns 811,665 shares of the biopharmaceutical company’s stock worth $1,112,000 after acquiring an additional 421,600 shares during the period. EAM Investors LLC bought a new stake in Marinus Pharmaceuticals in the third quarter worth about $554,000. Granite Point Capital Management L.P. raised its position in Marinus Pharmaceuticals by 250.3% in the third quarter. Granite Point Capital Management L.P. now owns 2,684,848 shares of the biopharmaceutical company’s stock worth $15,760,000 after acquiring an additional 1,918,400 shares during the period. KCG Holdings Inc. raised its position in Marinus Pharmaceuticals by 29.5% in the first quarter. KCG Holdings Inc. now owns 64,539 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 14,692 shares during the period. Finally, Perceptive Advisors LLC bought a new stake in Marinus Pharmaceuticals in the third quarter worth about $8,527,000. 49.77% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/12/07/marinus-pharmaceuticals-mrns-stock-rating-lowered-by-bidaskclub.html.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Receive News & Ratings for Marinus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.